CTOs on the Move

Halberd Corporation

www.halberdcorporation.com

 
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential ...
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Mitchell Felder
Chief Technical Officer Profile

Similar Companies

Carter Bloodcare

Carter Bloodcare is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bedford, TX. To find more information about Carter Bloodcare, please visit www.carterbloodcare.org

Medevco

Medevco is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

P-B Health Home Care Agency

P-B Health Home Care Agency is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affinergy, Inc.

Affinergy, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Durham, NC. To find more information about Affinergy, Inc., please visit www.affinergy.com

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.